Skip to Content

Altimmune to Announce First Quarter 2018 Financial Results on May 16

May 08, 2018

GAITHERSBURG, Md., May 08, 2018 (GLOBE NEWSWIRE) -- Altimmune, Inc. (Nasdaq:ALT), a clinical-stage immunotherapeutics company, today announced that it will announce financial results for the first quarter ended March 31, 2018 before the market open and host a conference call on Wednesday, May 16.

Conference Call Details
Date:                            Wednesday, May 16
Time:                            8:30am Eastern Time
Domestic:                      888-394-8218
International:                 323-701-0225
Conference ID:               1336227
Webcast:                        http://public.viavid.com/index.php?id=129546

Replays, Available through May 30th:
Domestic:                       844-512-2921
International:                  412-317-6671
Replay PIN:                     1336227

About Altimmune
Altimmune is a clinical-stage immunotherapeutics company focused on the development of products to stimulate robust and durable immune responses for the prevention and treatment of disease including NasoVAX, a Phase 2 seasonal influenza vaccine candidate, and HepTcell, a Phase 1 immunotherapeutic candidate for the potential cure of chronic hepatitis B. The company also has two United States government funded, next-generation anthrax vaccine candidates that are intended to improve protection and safety while having favorable dosage and storage requirements compared to other anthrax vaccines.

Contacts:
Bill Enright                                                                                                           
President and CEO                                                                                        
Phone: 240-654-1450                                                                                    
enright@altimmune.com 

Ashley Robinson
LifeSci Advisors, LLC
617-535-7742
arr@lifesciadvisors.com                                                                         

 

Primary Logo

Source: Altimmune, Inc.